Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes

NEXT STORY
Pluristem CEO Issues Shareholder Update on Clinical Programs
PREV STORY
Teleflex Announces Positive Data Emphasizing the Effectiveness of the UroLift® System Treatment for Enlarged Prostate Across Broad Patient Populations
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

author_avatar
NASDAQ Market News

Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly ...

author_avatar
NASDAQ Market News

Aptevo Therapeutics Augments Leadership Team

Appoints Former GlaxoSmithKline Executive Randy Maddux Senior Vice President, Operations Jane Gross, Ph.D., Promoted to ...

author_avatar
NASDAQ Market News